This inventor holds 4 USPTO granted patents and 2 published patent applications, plus 2 CIPO patents. Top assignees: British Columbia Cancer Agency Branch, Oslo University Hospital, The Board of Regents of the University of Nebraska. Active years: 2012-2021.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
Location History:
- Wuerzburg, DE (2012)
- Wrzburg, DE (2018)
- Wurzburg, DE (2020)
- Würzburg, DE (2021)
Company Filing History:
4 out of 66 
4 out of 12 
4 out of 971 
Years Active: 2012-2021
Title: Spotlight on Hans-Konrad Muller-Hermelink: Innovator in Lymphoma Research
Introduction: Hans-Konrad Muller-Hermelink, a distinguished inventor hailing from Wurzburg, Germany, has made significant contributions to the field of lymphoma research. With four patents to his name, his work focuses on utilizing gene expression data to enhance the identification, diagnosis, and prediction of survival in lymphoproliferative disorders such as diffuse large B cell lymphoma (DLBCL).
Latest Patents: Hans-Konrad Muller-Hermelink's latest patents include a groundbreaking survival predictor for DLBCL. This invention introduces methods and materials that leverage gene expression-based algorithms to predict the survival outcomes of DLBCL patients. Furthermore, his innovative microarray, the Lymph Dx microarray, enables the extraction of crucial gene expression data from lymphoma samples, facilitating more accurate diagnostic and predictive capabilities for lymphomas.
Career Highlights: Throughout his career, Muller-Hermelink has collaborated with esteemed institutions such as the United States of America, represented by the Department of Health and Human Services, and the University of Nebraska. His research and patents have paved the way for advancements in personalized therapeutic approaches for lymphoma patients, based on individual gene expression patterns.
Collaborations: Hans-Konrad Muller-Hermelink has had the privilege of working alongside notable coworkers in the field of lymphoma research, including Wyndham H Wilson and Richard I Fisher. Together, they have contributed to the development of methodologies and tools that have revolutionized the way lymphoproliferative disorders are understood and treated.
Conclusion: Hans-Konrad Muller-Hermelink's dedication to lymphoma research and his innovative approach to utilizing gene expression data have significantly impacted the field of oncology. His patents and collaborations stand as a testament to his commitment to advancing the diagnosis, treatment, and prognosis of lymphoproliferative disorders, ultimately improving outcomes for patients worldwide.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile